The case for & against
Bull & Bear analysis
Bullish
Bausch Health Companies Inc. (NYSE: BHC) is a leading global health company focused on the development and commercialization of innovative pharmaceuticals and medical devices, primarily in the specialties of dermatology, ophthalmology, and gastrointestinal disorders. The company operates through various segments, including Salix, Solta, and Diversified, positioning itself strategically within dynamic therapeutic markets amid ongoing regulatory challenges and competitive pressures.
Bull says
- ↑Q1 2026 revenue of $2.524 B (+14% YoY)
- ↑Q1 adjusted EBITDA reached $837 M (+27% YoY)
- ↑SHIBO acquisition drove Solta revenue up 193% in China
- ↑Net debt cut by >$100 M in Q1 improves leverage
- ↑Analysts raised price target to $8 on earnings revisions
- ↑High earnings yield and strong growth factors support valuation
Bear says
- ↓High leverage ratio magnifies losses if headwinds hit
- ↓Weak profitability factor signals potential margin pressure
- ↓Generic Xifaxan launch in Jan 2028 could erode revenue
- ↓Potential IRA pricing cuts may hurt key drug margins
- ↓Negative momentum factor deters short-term stock rallies
- ↓Low dividend yield limits shareholder cash returns
Earnings Call · Q1 2026 · Mgmt. Guidance
Updated 05-10-2026bullish
Transcript signals
Bull points
- Revenue was $2,524,000,000, up 12% on the reported basis and 7% on an organic basis compared to the same period a year ago.
- Adjusted EBITDA was $837 million, an increase of $176 million, or a 27% increase year-over-year.
- We delivered in Q1 the 12 consecutive quarter of year-over-year revenue and adjusted EBITDA growth, demonstrating once again the consistency of our operational execution.
Bear points
- we are excited about initiatives underway across the portfolio to ensure we plant the seeds for future growth. A few examples from different segments illustrate the breadth of that progress. Within U.S. capital deployment, we are focusing our resources on high growth opportunities that drive demand and operational efficiency. At Salix, this approach continues to translate into strong performance for Xifaxan, supported by high levels of physician engagement, improved patient access, and a channel mix that reinforce both stability and scale. We are investing thoughtfully. prioritizing returns and optimizing growth that can be realized from a highly resilient, well-established franchise. Turning to Solta China, we are pleased with our integration of the Shibo distribution business, which is progressing as planned. By deepening our vertical integration within this core market, this acquisition secures a critical segment of our value chain, providing unfiltered visibility into end consumer behavior, enabling more precise demand forecasting and strengthening our long-term competitive advantage.
- In case we lose exclusivity before the 1st of January, 2028, what it does, as you know, is that basically it curtailed the free cash flow generation between now and the end of 2027. So that would translate into, in the absence of any other levers that we would put in place, the need to, you know, monetize some of our assets earlier than originally planned.
Read full transcript analysis ›